论文部分内容阅读
以二乙基亚硝胺（ＤＥＮ）诱发大鼠肝癌，分别给予正常大鼠和肝癌大鼠干扰素（ＩＦＮα－２ｂ）、卡介苗（ＢＣＧ）或两者联用。从各组正常大鼠和肝癌大鼠肝中分离出枯否细胞（ＫＣ），体外与人肝癌细胞联合培养，分别测定培养液中的ＴＮＦ和ＩＬ－１含量。从未用免疫制剂的肝癌大鼠肝中分离出ＫＣ，体外培养给予ＩＦＮα－２ｂ、ＢＣＧ或两者联用，测定ＴＮＦ和ＩＬ－１。结果显示：ＩＦＮα－２ｂ或ＢＯＧ均促进ＫＣ（正常和肝癌大鼠，在体和离体）释放ＴＮＦ和ＩＬ－１，并均以两者联用效果最佳，使ＫＣ释放ＴＮＦ为对照组的２～５倍，ＩＬ－１活力提高５０％～８０％。此结果为联用免疫制剂增强ＫＣ抗肝癌细胞的最佳效果提供了科学依据。
Rat hepatocellular carcinoma was induced by diethylnitrosamine (DEN), and IFNα-2b, BCG or BCG were administered to normal rats and hepatocellular carcinoma rats respectively. Kupffer cells (KCs) were isolated from the liver of each group of normal rats and hepatocarcinoma rats and cultured in vitro with human hepatoma cells. The contents of TNF and IL-1 in the culture fluid were determined respectively. KC was isolated from the livers of rats with hepatocellular carcinoma that had never been immunized, and IFNα-2b, BCG or both were incubated in vitro to determine TNF and IL-1. The results showed that both IFNα-2b and BOG promoted the release of TNF and IL-1 in KC (normal and hepatocarcinoma rats, in vivo and ex vivo) 2 to 5 times, IL-1 activity increased by 50% to 80%. This result provides a scientific basis for the combination of immune agents to enhance the best effect of KC against liver cancer cells.